BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16609993)

  • 1. Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls.
    Meier JJ; Nauck MA; Kask B; Holst JJ; Deacon CF; Schmidt WE; Gallwitz B
    World J Gastroenterol; 2006 Mar; 12(12):1874-80. PubMed ID: 16609993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.
    Meier JJ; Gallwitz B; Askenas M; Vollmer K; Deacon CF; Holst JJ; Schmidt WE; Nauck MA
    Diabetologia; 2005 Sep; 48(9):1872-81. PubMed ID: 16010522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects.
    Meier JJ; Gallwitz B; Kask B; Deacon CF; Holst JJ; Schmidt WE; Nauck MA
    Diabetes; 2004 Dec; 53 Suppl 3():S220-4. PubMed ID: 15561915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    Digestion; 1992; 52(3-4):214-21. PubMed ID: 1459356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans.
    Meier JJ; Goetze O; Anstipp J; Hagemann D; Holst JJ; Schmidt WE; Gallwitz B; Nauck MA
    Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E621-5. PubMed ID: 14678954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects.
    Meier JJ; Nauck MA; Siepmann N; Greulich M; Holst JJ; Deacon CF; Schmidt WE; Gallwitz B
    Metabolism; 2003 Dec; 52(12):1579-85. PubMed ID: 14669159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia.
    Meier JJ; Gallwitz B; Siepmann N; Holst JJ; Deacon CF; Schmidt WE; Nauck MA
    Diabetologia; 2003 Jun; 46(6):798-801. PubMed ID: 12764578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of gastric inhibitory polypeptide to inhibit pentagastrin-stimulated acid secretion in vagotomized human subjects.
    Simmons TC; Taylor IL; Maxwell V; Brown JC; Grossman MI
    Dig Dis Sci; 1981 Oct; 26(10):902-4. PubMed ID: 6793335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentagastrin-induced gastric acid secretion in the diabetic rats: role of insulin.
    Chang FY; Chen TS; Lee SD; Doong ML; Yeh GH; Wang PS
    Chin J Physiol; 2004 Dec; 47(4):175-81. PubMed ID: 15803750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
    Meier JJ; Nauck MA; Kranz D; Holst JJ; Deacon CF; Gaeckler D; Schmidt WE; Gallwitz B
    Diabetes; 2004 Mar; 53(3):654-62. PubMed ID: 14988249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.
    Christensen MB
    Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8.
    Nauck M; Schmidt WE; Ebert R; Strietzel J; Cantor P; Hoffmann G; Creutzfeldt W
    J Clin Endocrinol Metab; 1989 Sep; 69(3):654-62. PubMed ID: 2668324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans.
    Veedfald S; Vedtofte L; Skov-Jeppesen K; Deacon CF; Hartmann B; Vilsbøll T; Knop FK; Christensen MB; Holst JJ
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31665480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastric acid secretion in streptozotocin-diabetic female rats.
    Lin CY; Yeh GH; Hsu FC; Tsai SC; Lau CP; Pu HF; Yu HL; Tung YF; Wang PS
    Chin J Physiol; 1991; 34(2):179-86. PubMed ID: 1835692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-related differences in gastric acid secretion and response of gastric inhibitory polypeptide after oral glucose in male rats.
    Chung SC; Chen TS; Wang JW; Liu JY; Hwang CY; Hwang C; Day CH; Tsai SC; Tung YF; Liu YF
    Chin J Physiol; 1993; 36(4):219-23. PubMed ID: 8020336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GIP(3-30)NH
    Gasbjerg LS; Christensen MB; Hartmann B; Lanng AR; Sparre-Ulrich AH; Gabe MBN; Dela F; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    Diabetologia; 2018 Feb; 61(2):413-423. PubMed ID: 28948296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
    Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
    Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.